{"id":"W2245390479","doi":"10.1155/2006/876252","title":"Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Natalizumab; Alemtuzumab; Medicine; Daclizumab; Monoclonal antibody; Adalimumab; Infliximab; Immunology; Monoclonal antibody therapy; Transplantation; Monoclonal; Hematopoietic stem cell transplantation; Disease; Antibody; Multiple sclerosis; Internal medicine; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006994009,0.0007957671,0.001980088,0.001245664,0.001368718,0.005175393,0.001233248,0.01136252,0.00686659],"category_scores_gemma":[0.01367061,0.0003720013,0.000868674,0.001821865,0.00289146,0.009810275,0.001560167,0.01317042,0.004103817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002015481,"about_ca_system_score_gemma":0.002457641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001664305,"about_ca_topic_score_gemma":0.004275587,"domain_scores_codex":[0.9974367,0.0005155695,0.0003349248,0.0002771542,0.001148763,0.0002868881],"domain_scores_gemma":[0.987973,0.005960196,0.001028785,0.0002782569,0.003014015,0.001745781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005365494,0.0001132031,0.0009945012,0.001043905,0.00006831519,0.0006870643,0.0001350875,0.0001296151,0.0007563641,0.0149297,0.5629727,0.4176329],"study_design_scores_gemma":[0.0000805054,0.0001613341,0.0005247557,0.0004697482,0.00003359079,0.0009362033,0.0001198026,0.00006374401,0.0001819747,0.003825691,0.9935831,0.00001951308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0009085177,0.4529067,0.0004548193,0.5091885,0.03144293,0.00001017704,0.00008893498,0.00005544012,0.004943972],"genre_scores_gemma":[0.008880511,0.6144696,0.001085279,0.2406876,0.1237864,0.00002467207,0.0001476468,0.00006969688,0.01084857],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.01136252,"threshold_uncertainty_score":0.03698832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003049635077120726,"score_gpt":0.2267193224542835,"score_spread":0.2236696873771628,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}